Blog

A new interesting article has been published in Kardiologiia. 2019 Dec 11; 59(11):14-20. doi: 10.18087/cardio.2019.11.n723. and titled:

[Acute Coronary Syndrome Registry of High Risk Patients: 30-Day Outcome].

Authors of this article are:

Lomakin NV, Buryachkovskaya LI, Sumarokov AB, Gerasimov AN, Gabbasov ZA.

A summary of the article is shown below:

AIM: The aim of the study is to evaluate important additional cardiovascular (CV) risk factors of major adverse cardiac events (MACE) in patients with acute coronary syndrome (ACS) during the first 30 days after index event.MATERIALS AND METHODS: Overall 750 patients with ACS were enrolled in the single center prospective registry from 2012-2015yy. 569 patients received dual antiplatelet therapy and in 425 cases platelet function testing (PFT) were performed. Most of the patients characterized as high risk elderly patients with multiple CV risk factors and high comorbidity index.RESULTS: At 30-day follow-up the mortality rate was 10,1%. Singlevariate analysis showed strong association between MACE and age, atrial fibrillation, stroke, chronic kidney disease, low ejection fraction, type 2 myocardial infarction (T2MI). Multivariate analysis showed that high-on-treatment platelet reactivity (PFT> 45%) with odds ratio 4.418 (p=0.0001), chronic kidney disease (OR 6.538 p=0.001) and T2MI (OR 1.925 p=0.0001) were significantly associated with adverse outcome.CONCLUSION: ACS registry showed high mortality level in real-life practice compared with randomized clinical trials due to the high prevalence of elderly patients with high comorbidity index. Patients with T2MI have significantly more severe prognosis and chronic kidney disease associated with increased MACE. PFT in this category of patients is reasonable for more accurate risk stratification.

Check out the article’s website on Pubmed for more information:

This article is a good source of information and a good way to become familiar with topics such as: Aged; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Registries; Risk Factors; Treatment Outcome.

---

NativeFolder: The Only Bacterial Culture Medium for the Expression of Soluble Proteins

---

Interference Test Kit for Assay Validation

---

Rheumatoid Factor Interference Blocker

---

New Antibodies from MOLECULAR DEPOT

---

New Proteins from MOLECULAR DEPOT

---

New Chemicals from MOLECULAR DEPOT